LangdonLMillerMD

PubMed

• 44 citations
  ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models
  Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langd...> ;Blood. 2021 Jun 17
• 189 citations
  A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia
  Susan O'Brien, Nicole Lamanna, Thomas J. Kipps, Ian W. Flinn, Andrew D. Zelenetz, Jan A. Burger, Michael J. Keating, Siddhartha Mitra, Leanne Holes, Albert S. Yu, Davi...> ;Blood. 2015 Dec 17
• 483 citations
  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
  Jennifer R. Brown, John C. Byrd, Steven Coutre, Don M. Benson, Ian W. Flinn, Nina D. Wagner-Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste M. Bello, Heather K. W...> ;Blood. 2014 May 29
• 176 citations
  Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.
  Ian W. Flinn, Brad S. Kahl, John P. Leonard, Richard R. Furman, Jennifer R. Brown, John C. Byrd, Nina D. Wagner-Johnston, Steven Coutre, Don M. Benson, Sissy Peterman,...> ;Blood. 2014 May 29
• Dual-site sampling improved detection rates for MRSA colonization in patients with cutaneous abscesses.
  May, L.,McCann, C.,Brooks, G.,Rothman, R.,Miller, L.,Jordan, J.> ;Diagn. Microbiol. Infect. Dis.. 2014 Jun 25
• 819 citations
  PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
  Ajay K. Gopal, Brad S. Kahl, Sven de Vos, Nina D. Wagner-Johnston, Stephen J. Schuster, Wojciech Jurczak, Ian W. Flinn, Christopher R. Flowers, Peter Martin, Andreas V...> ;The New England Journal of Medicine. 2014 Mar 12
• 1279 citations
  Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
  Richard R. Furman, Jeff P. Sharman, Steven Coutre, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W....> ;The New England Journal of Medicine. 2014 Mar 12
• 113 citations
  PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymp...
  Sarah A. Meadows, Francisco Vega, Adam Kashishian, Dave Johnson, Volker Diehl, Langdon L. Miller, Anas Younes, Brian J. Lannutti> ;Blood. 2012 Feb 23
• 427 citations
  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
  Julia Hoellenriegel, Sarah A. Meadows, Mariela Sivina, William G. Wierda, Hagop M. Kantarjian, Michael J. Keating, Neill A. Giese, Susan O'Brien, Albert S. Yu, Langdon...> ;Blood. 2011 Sep 29
• A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or ben...
  Flinn IW, Schreeder MT, Coutre SE, Leonard J, Wagner-Johnston ND, De Vos S, Boccia RV, Holes L, Peterman S, Miller LL, Yu AS> ;J. Clin. Oncol.. 2011-05-20
• 9 citations
  Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis.
  Eitan Kerem, Michael Wilschanski, Nilsen L. Miller, Thea Pugatsch, Tali Magory Cohen, H. Blau, Joseph Rivlin, David Shoseyov, A. Reha, Scott Constantine, Temitayo Ajay...> ;Journal of Cystic Fibrosis. 2011 May 1
• 128 citations
  The 6‐minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations
  Craig M. McDonald, Erik K Henricson, Jay J. Han, R. Ted Abresch, Alina Nicorici, Leone Atkinson, Gary Elfring, A. Reha, Langdon L. Miller> ;Muscle & Nerve. 2010 Dec 1
• 173 citations
  Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis
  Isabelle Sermet-Gaudelus, Kris De Boeck, Georges Casimir, François Vermeulen, Teresinha Leal, Agnès Mogenet, Delphine Roussel, Janine Fritsch, Laurence Hanssens, Samit...> ;American Journal of Respiratory and Critical Care Medicine. 2010 Nov 15
• 279 citations
  The 6-minute walk test as a new outcome measure in duchenne muscular dystrophy
  Craig M. McDonald, Erik K Henricson, Jay J. Han, R. Ted Abresch, Alina Nicorici, Gary Elfring, Leone Atkinson, A. Reha, Samit Hirawat, Langdon L. Miller> ;Muscle & Nerve. 2010 Apr 1
• 287 citations
  Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial
  Eitan Kerem, Samit Hirawat, S. Armoni, Yasmin Yaakov, David Shoseyov, Michael Cohen, Malka Nissim-Rafinia, H. Blau, Joseph Rivlin, Micha Aviram, Gary Elfring, Valerie ...> ;Lancet. 2008 Aug 30
• 270 citations
  Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
  Marc Buyse, Tomasz Burzykowski, Kevin Carroll, Stefan Michiels, Daniel J. Sargent, Langdon L. Miller, Gary L. Elfring, Jean Pierre Pignon, Pascal Piedbois> ;Journal of Clinical Oncology. 2007 Nov 20
• 862 citations
  PTC124 targets genetic disorders caused by nonsense mutations
  Ellen Welch, Elisabeth R. Barton, Jin Zhuo, Yuki Tomizawa, Westley J. Friesen, Panayiota Trifillis, Sergey Paushkin, Meenal Patel, Christopher R. Trotta, Seongwoo Hwan...> ;Nature. 2007 May 3
• 196 citations
  Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy M...
  Samit Hirawat, Ellen Welch, Gary Elfring, Valerie Northcutt, Sergey Paushkin, Seongwoo Hwang, Eileen M. Leonard, Neil Gregory Almstead, William D. Ju, Stuart W. Peltz,...> ;Journal of Clinical Pharmacology. 2007 Apr 1
• 22 citations
  A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced s...
  Henry C. Pitot, Alex A. Adjei, Joel M. Reid, Jeff A. Sloan, Pamela J. Atherton, Joseph Rubin, Steven R. Alberts, Barbara A. Duncan, Louis Denis, Larry J. Schaaf, Dongh...> ;Cancer Chemotherapy and Pharmacology. 2006 Aug 1
• 29 citations
  Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction
  Larry J. Schaaf, Lisa A. Hammond, Stuart J. Tipping, Richard M. Goldberg, Rakesh Goel, John G. Kuhn, Langdon L. Miller, Linda D. Compton, Laura Cisar, Gary Elfring, Ga...> ;Clinical Cancer Research. 2006 Jun 15
• 12 citations
  A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and et...
  Anne L. Angiolillo, Virginia Davenport, Mary Ann Bonilla, Carmella van de Ven, Janet Ayello, O. Militano, Langdon L. Miller, Mark Krailo, Gregory H. Reaman, Mitchell S...> ;Clinical Cancer Research. 2005 Apr 1
• 486 citations
  Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer De...
  Caio Max S. Rocha Lima, Mark R. Green, Robert Rotche, Wilson H. Miller, G. Mark Jeffrey, Laura Cisar, Adele Morganti, Nicoletta Orlando, Gabriela Gruia, Langdon L. Miller> ;Journal of Clinical Oncology. 2004 Sep 15
• A case for time to tumor progression (TTP) as the primary (1o) efficacy endpoint in 1st-line metastatic colorectal cancer (MCRC) therapy: Correlation of TTP and overal...
  Miller LL, Elfring GL, Gruia G, Hirawat S, Douillard JY, Saltz LB> ;J. Clin. Oncol.. 2004-07-15
• 23 citations
  Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation.
  Charles A. Linker, Paolo Anderlini, Roger H. Herzig, N. P. Christiansen, George Somlo, William I. Bensinger, Joseph W. Fay, Joseph P. Lynch, Lawrence T. Goodnough, Mar...> ;Biology of Blood and Marrow Transplantation. 2003 Jun 1
• 85 citations
  Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
  Timothy F. Cloughesy, Emese Filka, John G. Kuhn, Gillian Nelson, Fairooz F. Kabbinavar, Henry S. Friedman, Langdon L. Miller, Gary Elfring> ;Cancer. 2003 May 1
• Join now to see all

Abstracts/Posters

• LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease
  Langdon L Miller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019